Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023

September 25, 2013

Reportbuyer.com just published a new market research report: Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023.

London (PRWEB) September 25, 2013

Report Details

Contract manufacturing for pharma – discover top companies' revenue prospects

How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.

That way you find information you need on established and emerging companies. Learn on to scan those organisations and see what their future market could be worth.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.

There you also gain 141 tables, 58 charts, and five interviews with the industry.

Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:

•Finished dosage formulations (FDF) manufacturing

•Active pharmaceutical ingredients (API) production.

See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.

Company profiles – activities, results, competition, and prospects

Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:

•Overview of the company's contract manufacturing services, including clients

•Analysis of recent financial performance – overall revenue and that for CMO services

•Assessment of developments – acquisitions, capacity expansions, new service offerings, and collaborations

•SWOT analysis of the company – strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023

•Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies

•Transcript of an interview by visiongain, for five of the companies.

Discover there what participants achieve, do, and say, helping you stay ahead.

European contract manufacturing organisations

First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:


•Evonik Degussa

•Royal DSM

•Boehringer Ingelheim Biopharmaceuticals



•Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.

Companies based in the US and Japan

Next, our report shows you developments and sales outlooks to 2023 for five other companies:

•Catalent Pharma Solutions


•AbbVie Contract Manufacturing

•Daito Pharmaceutical

•Pfizer CentreSource.

Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.

Developed-market API specialists

You also discover outlooks for four top producers of active pharma ingredients:

•Teva API

•Esteve Química



Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.

India and China – analysis of pharma manufacturing service providers

Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:

•Dr. Reddy's Laboratories

•Aurobindo Pharma

•Divis Laboratories

•Shandong Xinhua Pharmaceutical

•Zhejiang Hisun Pharmaceutical

•Zhejiang Huahai Pharmaceuticals.

That way you find sales data and underlying trends, seeing what the present and future hold.

Predictions for the worldwide pharma CMO market and submarkets

Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.

There you see overall world revenues in 2017 reaching $66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.

Biologics and biosimilars also hold promise. New biological therapies – including antibody-drug conjugates and regenerative medicines – interest CMOs and clients.

Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.

Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you

In particular, our new investigation gives you the following knowledge:

•Revenues to 2023 for the world CMO market and its components – discover that industry's prospects, finding promising places for investments and revenues

•Profiles of 30 leading companies – assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations

•Interviews with 5 companies in the CMO industry – discover debates and opinions to help you stay ahead

•Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business

•Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages

•Outlooks for established players and firms entering the sector – explore needs, practices, and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Prospects for pharma manufacturing providers – gain by ordering now

Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out – please order our new report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6



AbbVie Contract Manufacturing

Abic (part of Teva)

Activa Capital

Aegerion Pharmaceuticals


Aerofarm (part of Fareva)

Aesica Pharmaceuticals

Agence Nationale de sécurité du Médicament et des produits de santé (ANSM) [France]

Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]


Ajinomoto OmniChem

AlgoNomics (part of Lonza)

Alliance Medical Products (part of Siegfried)

Almac Group





Archimica (part of Euticals)


Astellas Pharma


Athera Biotechnologies

Aurobindo Pharma

AuroSource (part of Aurobindo Pharma)

Avalanche Biotechnologies

Banner Pharmacaps (part of Patheon)


Barr-Pliva (part of Teva)



BC Partners

Beijing Double-Crane Pharmaceutical (BDCP)

Bellwyck Packaging Solutions

Bend Research

Bentley Pharma (part of Teva)



Blackstone Group

Boehringer Ingelheim

Boehringer Ingelheim Biopharmaceuticals


Bristol-Myers Squibb



Cardinal Health

Catalent (Shanghai) Clinical Trial Supplies Co

Catalent Pharma Solutions


Celldex Therapeutics

CEVEC Pharmaceuticals



China National Pharmaceutical Group (Sinopharm)

Chirotech Technology (part of Dr. Reddy's Laboratories)

Cleveland BioLabs

Cobra Biologics Holding

CordenPharma (part of ICIG)

CPM ContractPharma (part of Aenova)


Daiichi Sankyo

Daito Pharmaceutical

DecImmune Therapeutics

Delmas Perfusion


DiFUSION Technologies

Divis Laboratories

Dr. Reddy's Laboratories

DSM Sinochem Pharmaceuticals

Durham University

Eclipse Therapeutics (part of Bionomics)

Eindhoven University of Technology


Eli Lilly


Enobia Pharma (now Alexion Pharmaceuticals)

Enzon Pharmaceuticals


Esteve Química (part of Esteve)

Euro Vital Pharma (part of Aenova)

European Medicines Agency (EMA)


Evonik Degussa (part of Evonik Industries)

Evonik Industries

Excella (part of Fareva)

Excelvision (part of Fareva)




Farma Lepori (part of Angelini Group)

Farmaclair (part of Fareva)


Farmea (part of Fareva)

Food and Drug Administration (FDA) [US]

Frazier Healthcare

Fuyang Xinghai Investment

Genentech (part of Roche)

Générique Même Médicament (GEMME) [France]

Genzyme (part of Sanofi)

Gilead Sciences


Gyma Laboratories of America

Haupt Pharma

Health and Safety Executive (HSE) [UK]

Health Canada

Hisun-Pfizer Pharmaceuticals

Human Genome Sciences (part of GSK)

ICI (Imperial Chemical Industries)

Immune Pharmaceuticals

Indoco Remedies

Instituto de Angeli (part of Fareva)

Intellect Neurosciences

International Chemical Investors Group (ICIG)



Ivax API (part of Teva)


JK Pharmaceutical

Laboratoire Aguettant

Laboratoires Besins



Marinopoulos Group

Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]

Merck & Co.

Merck KGaA


Molecular Partners


National Institutes of Health (NIH) [US]

National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]

New Jersey Institute of Technology



OctoPlus (part of Dr. Reddy's Laboratories)

OmniChem (part of Ajinomoto OmniChem)

OncoMed Pharmaceuticals

Osiris Therapeutics

Otsuka Pharmaceutical


Paranta Biosciences




PFC (now Teva PFC)


Pfizer CentreSource (part of Pfizer)


Piramal Pharma Solutions (part of Piramal Enterprises)

Plantex (part of Teva)

Poli Industria Chimica (part of Euticals)


Prosintex Química

R5 Pharmaceuticals (part of Aesica Pharmaceuticals)


Ranbaxy Laboratories (part of Daiichi Sankyo)

Recepta Biopharma


Redwood Bioscience

Respirics (part of Zhejiang Hisun Pharmaceutical)


Royal DSM

Saltigo (part of Lanxess)

Sandoz (part of Novartis)


Sanwa Kagaku Kenkyusho Co


Seattle Genetics

Sentry BioPharma Services


Shandong Xinhua Pharmaceutical (Europe) (part of Shandong Xinhua Pharmaceutical)

Shandong Xinhua Pharmaceutical Co

Shanghai Pharmaceutical Co



Sicor Biotech (part of Teva)


Sigmar Italia (part of Fareva)

Silverfleet Capital



Softigel (part of Procaps)

State Food and Drug Administration (SFDA) [China]

SurModics (part of Evonik Industries)


SwissCo Services (part of Aenova)


Takeda Pharmaceutical Company

Temmler Group (part of Aenova)

Temmler Ireland (part of Aenova)

Temmler Italia (part of Aenova)

Temmler Pharma (part of Aenova)

Temmler Werke (part of Aenova)

Tessenderlo Group

Teva API

Teva Pharmaceutical Industries

Théramax (part of Teva)

Thermo Fisher Scientific

Tianjin Tianyo Pharmaceuticals

Tianma Tianji


UMN Pharma


University of Bradford

University of Leeds

Valdepharm (part of Fareva)

Vetter Pharma


Vivante GMP Solutions (part of Lonza)

VTU Technology

Wanhuai Beijing Double-Crane Pharmaceutical (part of BDCP)

West Pharmaceutical Services

Xinhua Pharmaceutical (Gaomi) Company (part of Shandong Xinhua Pharmaceutical)


Yiwu Huayi Investment

Zenara Pharmaceuticals

Zhejiang Hisun Pharmaceutical

Zhejiang Huahai Pharmaceutical

Zhejiang Jiang Yuan Tang Biotechnology

Zibo Xinhua-Perrigo Pharmaceutical Company

Read the full report:

Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023


For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11160582.htm

Source: prweb

comments powered by Disqus